表紙
市場調査レポート

大腸癌治療薬の世界市場:2015〜2019年

Global Colorectal Cancer Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 333145
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
大腸癌治療薬の世界市場:2015〜2019年 Global Colorectal Cancer Drugs Market 2015-2019
出版日: 2015年06月17日 ページ情報: 英文 125 Pages
概要

大腸癌は、米国で3番目に多い癌です。生活習慣の変化や加齢、遺伝子疾患、家族歴、炎症性腸疾患などが大腸癌のリスクファクターとなっています。便潜血、食欲減退、便秘、体重減少、吐き気、腹部膨満、骨盤痛などの症状があります。手術、化学療法、生物学的療法、放射線療法などの治療法があります。世界の大腸癌治療薬市場は、2014〜2019年にかけCAGR3.62%で拡大すると予測されています。

当レポートでは、世界の大腸癌治療薬市場について詳細に分析し、市場の動向と2015〜2019年の成長見通し、分子タイプ別、投与ルート別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

第4章 市場調査方法

第5章 イントロダクション

第6章 疾患概要

  • 疾患の理解
  • 病態生理学
  • 疫学
  • 診断
  • 病期
  • 管理
  • 経済的負担

第7章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 分子タイプ別市場セグメンテーション

  • 小分子
  • 生物製剤

第9章 投与ルート別市場セグメンテーション

  • 経口
  • 非経口

第10章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第11章 主要国

  • 米国
  • 日本
  • ドイツ
  • スペイン
  • 中国

第12章 購入基準

第13章 市場成長促進因子

第14章 促進因子とその影響

第15章 市場の課題

第16章 促進因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー環境

  • 競合シナリオ
  • 市場シェア調査:2014年
  • その他の将来的見込みのあるベンダー

第20章 主な動向

第21章 主要ベンダー調査

  • Amgen
  • Bayer
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd.
  • Merck Serono
  • Sanofi SA

第22章 当シリーズの他のレポート

図表

目次
Product Code: IRTNTR6118

About Colorectal Cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.

Based on the type of molecule, the market is grouped into two categories:

  • Biologics
  • Small molecules

Based on the route of administration, the market is grouped into two categories:

  • Oral
  • Parenteral

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:

  • Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
  • EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
  • APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Serono

Other Prominent Vendors

  • Accord Healthcare
  • Advenchen Laboratories
  • Aeterna Zentaris
  • AstraZeneca
  • Bavarian Nordic
  • Biothera
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Debiopharm
  • Eisai
  • Eli Lilly
  • Immodulon Therapeutics
  • Mologen
  • Mylan
  • Nektar Therapeutics
  • Oncothyreon
  • Otsuka Pharmaceutical
  • Precision Biologics
  • Sun Pharmaceutical
  • Symphogen
  • Taiho
  • Takeda
  • Teva
  • ThromboGenics
  • Xbiotech
  • Yakult Honsha

Market Driver

  • Increase in population of patients
  • For a full, detailed list, view our report

Market Challenge

  • Loss of patent exclusivity
  • For a full, detailed list, view our report

Market Trend

  • Dominance of biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Pathophysiology
  • 06.3. Epidemiology
  • 06.4. Diagnosis
  • 06.5. Staging
    • 06.5.1. Staging: Colon Cancer
    • 06.5.2. Staging: Rectal Cancer
  • 06.6. Management
  • 06.7. Economic Burden

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
    • 07.2.1. Colorectal Cancer Drugs Market in US
    • 07.2.2. Colorectal Cancer Drugs Market in Germany
    • 07.2.3. Colorectal Cancer Drugs Market in Spain
    • 07.2.4. Colorectal Cancer Drugs Market in Japan
    • 07.2.5. Colorectal Cancer Drugs Market in China
  • 07.3. Five Forces Analysis

08. Market Segmentation by Type of Molecules

  • 08.1. Small molecules
  • 08.2. Biologics

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Parenteral

10. Geographical Segmentation

  • 10.1. Colorectal Cancer Drugs Market in Americas
    • 10.1.1. Market Size and Forecast
  • 10.2. Colorectal Cancer Drugs Market in EMEA
    • 10.2.1. Market Size and Forecast
  • 10.3. Colorectal Cancer Drugs Market in APAC
    • 10.3.1. Market Size and Forecast

11. Key Leading Countries

  • 11.1. US
  • 11.2. Japan
  • 11.3. Germany
  • 11.4. Spain
  • 11.5. China

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Competitive Assessment of Top Drugs for Colorectal Cancer
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. Merck Serono
    • 19.2.4. Bristol-Myers Squibb
    • 19.2.5. Amgen
    • 19.2.6. Sanofi
    • 19.2.7. Bayer
  • 19.3. Other and Future Prominent Vendors

20. Key Takeaways

21. Key Vendor Analysis

  • 21.1. Amgen
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Product Portfolio by Revenue 2013
    • 21.1.5. Business Segmentation by Revenue 2012 and 2013
    • 21.1.6. Geographical Segmentation by Revenue 2013
    • 21.1.7. Business Strategy
    • 21.1.8. Recent Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Bayer
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Business segmentation by revenue 2014
    • 21.2.4. Business segmentation by revenue 2013 and 2014
    • 21.2.5. Geographical segmentation by revenue 2014
    • 21.2.6. Business strategy
    • 21.2.7. Recent developments
    • 21.2.8. SWOT analysis
  • 21.3. Bristol-Myers Squibb Co.
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Key Product Offerings
    • 21.3.4. Revenue by Geography
    • 21.3.5. Business Strategy
    • 21.3.6. Key Information
    • 21.3.7. SWOT Analysis
  • 21.4. F. Hoffmann-La Roche Ltd.
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Sales by Geography
    • 21.4.6. Business Strategy
    • 21.4.7. Key Information
    • 21.4.8. SWOT Analysis
  • 21.5. Merck Serono
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Geographical Segmentation by Revenue 2013
    • 21.5.4. Business Strategy
    • 21.5.5. Recent Developments
    • 21.5.6. SWOT Analysis
  • 21.6. Sanofi SA
    • 21.6.1. Key Facts
    • 21.6.2. Business Description
    • 21.6.3. Business Segmentation
    • 21.6.4. Revenue by Business Segmentation
    • 21.6.5. Revenue Comparison 2012 and 2013
    • 21.6.6. Sales by Geography
    • 21.6.7. Business Strategy
    • 21.6.8. Key Developments
    • 21.6.9. SWOT Analysis

22. Other Reports in this Series

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Pathophysiology
  • 06.3. Epidemiology
  • 06.4. Diagnosis
  • 06.5. Staging
    • 06.5.1. Staging: Colon Cancer
    • 06.5.2. Staging: Rectal Cancer
  • 06.6. Management
  • 06.7. Economic Burden

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
    • 07.2.1. Colorectal Cancer Drugs Market in US
    • 07.2.2. Colorectal Cancer Drugs Market in Germany
    • 07.2.3. Colorectal Cancer Drugs Market in Spain
    • 07.2.4. Colorectal Cancer Drugs Market in Japan
    • 07.2.5. Colorectal Cancer Drugs Market in China
  • 07.3. Five Forces Analysis

08. Market Segmentation by Type of Molecules

  • 08.1. Small molecules
  • 08.2. Biologics

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Parenteral

10. Geographical Segmentation

  • 10.1. Colorectal Cancer Drugs Market in Americas
    • 10.1.1. Market Size and Forecast
  • 10.2. Colorectal Cancer Drugs Market in EMEA
    • 10.2.1. Market Size and Forecast
  • 10.3. Colorectal Cancer Drugs Market in APAC
    • 10.3.1. Market Size and Forecast

11. Key Leading Countries

  • 11.1. US
  • 11.2. Japan
  • 11.3. Germany
  • 11.4. Spain
  • 11.5. China

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Competitive Assessment of Top Drugs for Colorectal Cancer
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. Merck Serono
    • 19.2.4. Bristol-Myers Squibb
    • 19.2.5. Amgen
    • 19.2.6. Sanofi
    • 19.2.7. Bayer
  • 19.3. Other and Future Prominent Vendors

20. Key Takeaways

21. Key Vendor Analysis

  • 21.1. Amgen
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Product Portfolio by Revenue 2013
    • 21.1.5. Business Segmentation by Revenue 2012 and 2013
    • 21.1.6. Geographical Segmentation by Revenue 2013
    • 21.1.7. Business Strategy
    • 21.1.8. Recent Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Bayer
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Business segmentation by revenue 2014
    • 21.2.4. Business segmentation by revenue 2013 and 2014
    • 21.2.5. Geographical segmentation by revenue 2014
    • 21.2.6. Business strategy
    • 21.2.7. Recent developments
    • 21.2.8. SWOT analysis
  • 21.3. Bristol-Myers Squibb Co.
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Key Product Offerings
    • 21.3.4. Revenue by Geography
    • 21.3.5. Business Strategy
    • 21.3.6. Key Information
    • 21.3.7. SWOT Analysis
  • 21.4. F. Hoffmann-La Roche Ltd.
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Sales by Geography
    • 21.4.6. Business Strategy
    • 21.4.7. Key Information
    • 21.4.8. SWOT Analysis
  • 21.5. Merck Serono
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Geographical Segmentation by Revenue 2013
    • 21.5.4. Business Strategy
    • 21.5.5. Recent Developments
    • 21.5.6. SWOT Analysis
  • 21.6. Sanofi SA
    • 21.6.1. Key Facts
    • 21.6.2. Business Description
    • 21.6.3. Business Segmentation
    • 21.6.4. Revenue by Business Segmentation
    • 21.6.5. Revenue Comparison 2012 and 2013
    • 21.6.6. Sales by Geography
    • 21.6.7. Business Strategy
    • 21.6.8. Key Developments
    • 21.6.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Drivers and Challenges of the Global Colorectal Cancer Drugs Market
  • Exhibit 3: Diagnosis of Colorectal Cancer
  • Exhibit 4: Management of Colorectal Cancer
  • Exhibit 5: A Snapshot of the Economic Burden of the Global Colorectal Cancer Drugs Market
  • Exhibit 6: Snapshot of the Global Colorectal Cancer Drugs Market
  • Exhibit 7: Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
  • Exhibit 8: Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 9: Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
  • Exhibit 10: Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
  • Exhibit 11: Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
  • Exhibit 12: Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
  • Exhibit 13: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
  • Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
  • Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
  • Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
  • Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
  • Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
  • Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
  • Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
  • Exhibit 21:
  • Exhibit 22: Drivers of the Global Colorectal Cancer Drugs Market
  • Exhibit 23: Challenges of the Global Colorectal Cancer Drugs Market
  • Exhibit 24: Trends of the Global Colorectal Cancer Drugs Market
  • Exhibit 25: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
  • Exhibit 26: F. Hoffmann-La Roche: Product Portfolio
  • Exhibit 27: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
  • Exhibit 28: Avastin: Region-wise Revenues 2010-2014 ($ millions)
  • Exhibit 29: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
  • Exhibit 30: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
  • Exhibit 31: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
  • Exhibit 32: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
  • Exhibit 33: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
  • Exhibit 34: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
  • Exhibit 35: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
  • Exhibit 36: YoY Revenues and Growth Rate of Xeloda in Europe 2010-2014 ($ millions)
  • Exhibit 37: YoY Revenues and Growth Rate of Xeloda in Japan 2010-2014 ($ millions)
  • Exhibit 38: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
  • Exhibit 39: Merck Serono: Product Portfolio
  • Exhibit 40: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
  • Exhibit 41: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
  • Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
  • Exhibit 43: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
  • Exhibit 44: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
  • Exhibit 45: Bristol-Myers Squibb: Product Portfolio
  • Exhibit 46: Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
  • Exhibit 47: Amgen: Product Portfolio
  • Exhibit 50: Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
  • Exhibit 51: Vectibix: Region-wise Revenues 2010-2014 ($ millions)
  • Exhibit 52: Sanofi: Product Portfolio
  • Exhibit 53: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
  • Exhibit 54: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
  • Exhibit 55: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
  • Exhibit 56: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
  • Exhibit 57: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
  • Exhibit 58: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
  • Exhibit 59: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
  • Exhibit 60: Zaltrap: Region-wise Revenue 2013-2014 ($ millions)
  • Exhibit 61: Bayer: Product Portfolio
  • Exhibit 62: Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
  • Exhibit 63: Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
  • Exhibit 64: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 65: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 66: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 67: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 68: Bayer: Business segmentation by revenue 2014
  • Exhibit 69: Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
  • Exhibit 70: Bayer: Geographical segmentation by revenue 2014
  • Exhibit 71: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 72: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 73: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 74: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 75: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 76: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 77: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 78: Sanofi SA: Business Segmentation
  • Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top